Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer

Sara Santagata, Maria Napolitano, Crescenzo D'Alterio, Sonia Desicato, Salvatore Di Maro, Luciana Marinelli, Alessandra Fragale, Maria Buoncervello, Francesco Persico, Lucia Gabriele, Ettore Novellino, Nicola Longo, Sandro Pignata, Sisto Perdonà, Stefania Scala

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

With the intent to identify biomarkers in renal cell carcinoma (RCC) the functional status of T-regulatory cells (Tregs) was investigated in primary RCC. Tregs were isolated from tumoral-(TT), peritumoral tissue-(PT) and peripheral blood-(PB) of 42 primary RCC patients and function evaluated through effector T cells (Teff) proliferation, cytokines release and demethylation of Treg Specific Region (TSDR). The highest value of Tregs was detected in TT with the uppermost amount of effector-Tregs-(CD4+CD25hiFOXP3hiCD45RA-). PB-RCC Tregs efficiently suppress Teffproliferation compared to healthy donor (HD)-Tregs and, at the intrapatient evaluation, TT-derived Tregs were the most suppressive. Higher demethylation TSDR was detected in TT- and PB-RCC Tregs vs HD-Tregs (P < 0,001). CXCR4 is highly expressed on Tregs, thus we wished to modulate Tregs function through CXCR4 inhibition. CXCR4 antagonism, elicited by a new peptidic antagonist, Peptide-R29, efficiently reversed Tregs suppression of Teffproliferation. Thus Tregs functional evaluation precisely reflects Tregs status and may be a reliable biomarker of tumoral immune response. In addition, treatment with CXCR4 antagonist, impairing Tregs function, could improve the anticancer immune response, in combination with conventional therapy and/or immunotherapy such as checkpoints inhibitors.

Original languageEnglish
Pages (from-to)77110-77120
Number of pages11
JournalOncotarget
Volume8
Issue number44
DOIs
Publication statusPublished - 2017

Fingerprint

Regulatory T-Lymphocytes
Renal Cell Carcinoma
Eragrostis
Biomarkers
Tissue Donors
Immunotherapy

Keywords

  • CXCR4
  • Immune suppression
  • Renal cell carcinoma
  • T regulatory cells
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. / Santagata, Sara; Napolitano, Maria; D'Alterio, Crescenzo; Desicato, Sonia; Di Maro, Salvatore; Marinelli, Luciana; Fragale, Alessandra; Buoncervello, Maria; Persico, Francesco; Gabriele, Lucia; Novellino, Ettore; Longo, Nicola; Pignata, Sandro; Perdonà, Sisto; Scala, Stefania.

In: Oncotarget, Vol. 8, No. 44, 2017, p. 77110-77120.

Research output: Contribution to journalArticle

Santagata, Sara ; Napolitano, Maria ; D'Alterio, Crescenzo ; Desicato, Sonia ; Di Maro, Salvatore ; Marinelli, Luciana ; Fragale, Alessandra ; Buoncervello, Maria ; Persico, Francesco ; Gabriele, Lucia ; Novellino, Ettore ; Longo, Nicola ; Pignata, Sandro ; Perdonà, Sisto ; Scala, Stefania. / Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. In: Oncotarget. 2017 ; Vol. 8, No. 44. pp. 77110-77120.
@article{98a858c27fa34cb7bac636ebd97c8164,
title = "Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer",
abstract = "With the intent to identify biomarkers in renal cell carcinoma (RCC) the functional status of T-regulatory cells (Tregs) was investigated in primary RCC. Tregs were isolated from tumoral-(TT), peritumoral tissue-(PT) and peripheral blood-(PB) of 42 primary RCC patients and function evaluated through effector T cells (Teff) proliferation, cytokines release and demethylation of Treg Specific Region (TSDR). The highest value of Tregs was detected in TT with the uppermost amount of effector-Tregs-(CD4+CD25hiFOXP3hiCD45RA-). PB-RCC Tregs efficiently suppress Teffproliferation compared to healthy donor (HD)-Tregs and, at the intrapatient evaluation, TT-derived Tregs were the most suppressive. Higher demethylation TSDR was detected in TT- and PB-RCC Tregs vs HD-Tregs (P < 0,001). CXCR4 is highly expressed on Tregs, thus we wished to modulate Tregs function through CXCR4 inhibition. CXCR4 antagonism, elicited by a new peptidic antagonist, Peptide-R29, efficiently reversed Tregs suppression of Teffproliferation. Thus Tregs functional evaluation precisely reflects Tregs status and may be a reliable biomarker of tumoral immune response. In addition, treatment with CXCR4 antagonist, impairing Tregs function, could improve the anticancer immune response, in combination with conventional therapy and/or immunotherapy such as checkpoints inhibitors.",
keywords = "CXCR4, Immune suppression, Renal cell carcinoma, T regulatory cells, Tumor microenvironment",
author = "Sara Santagata and Maria Napolitano and Crescenzo D'Alterio and Sonia Desicato and {Di Maro}, Salvatore and Luciana Marinelli and Alessandra Fragale and Maria Buoncervello and Francesco Persico and Lucia Gabriele and Ettore Novellino and Nicola Longo and Sandro Pignata and Sisto Perdon{\`a} and Stefania Scala",
year = "2017",
doi = "10.18632/oncotarget.20363",
language = "English",
volume = "8",
pages = "77110--77120",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "44",

}

TY - JOUR

T1 - Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer

AU - Santagata, Sara

AU - Napolitano, Maria

AU - D'Alterio, Crescenzo

AU - Desicato, Sonia

AU - Di Maro, Salvatore

AU - Marinelli, Luciana

AU - Fragale, Alessandra

AU - Buoncervello, Maria

AU - Persico, Francesco

AU - Gabriele, Lucia

AU - Novellino, Ettore

AU - Longo, Nicola

AU - Pignata, Sandro

AU - Perdonà, Sisto

AU - Scala, Stefania

PY - 2017

Y1 - 2017

N2 - With the intent to identify biomarkers in renal cell carcinoma (RCC) the functional status of T-regulatory cells (Tregs) was investigated in primary RCC. Tregs were isolated from tumoral-(TT), peritumoral tissue-(PT) and peripheral blood-(PB) of 42 primary RCC patients and function evaluated through effector T cells (Teff) proliferation, cytokines release and demethylation of Treg Specific Region (TSDR). The highest value of Tregs was detected in TT with the uppermost amount of effector-Tregs-(CD4+CD25hiFOXP3hiCD45RA-). PB-RCC Tregs efficiently suppress Teffproliferation compared to healthy donor (HD)-Tregs and, at the intrapatient evaluation, TT-derived Tregs were the most suppressive. Higher demethylation TSDR was detected in TT- and PB-RCC Tregs vs HD-Tregs (P < 0,001). CXCR4 is highly expressed on Tregs, thus we wished to modulate Tregs function through CXCR4 inhibition. CXCR4 antagonism, elicited by a new peptidic antagonist, Peptide-R29, efficiently reversed Tregs suppression of Teffproliferation. Thus Tregs functional evaluation precisely reflects Tregs status and may be a reliable biomarker of tumoral immune response. In addition, treatment with CXCR4 antagonist, impairing Tregs function, could improve the anticancer immune response, in combination with conventional therapy and/or immunotherapy such as checkpoints inhibitors.

AB - With the intent to identify biomarkers in renal cell carcinoma (RCC) the functional status of T-regulatory cells (Tregs) was investigated in primary RCC. Tregs were isolated from tumoral-(TT), peritumoral tissue-(PT) and peripheral blood-(PB) of 42 primary RCC patients and function evaluated through effector T cells (Teff) proliferation, cytokines release and demethylation of Treg Specific Region (TSDR). The highest value of Tregs was detected in TT with the uppermost amount of effector-Tregs-(CD4+CD25hiFOXP3hiCD45RA-). PB-RCC Tregs efficiently suppress Teffproliferation compared to healthy donor (HD)-Tregs and, at the intrapatient evaluation, TT-derived Tregs were the most suppressive. Higher demethylation TSDR was detected in TT- and PB-RCC Tregs vs HD-Tregs (P < 0,001). CXCR4 is highly expressed on Tregs, thus we wished to modulate Tregs function through CXCR4 inhibition. CXCR4 antagonism, elicited by a new peptidic antagonist, Peptide-R29, efficiently reversed Tregs suppression of Teffproliferation. Thus Tregs functional evaluation precisely reflects Tregs status and may be a reliable biomarker of tumoral immune response. In addition, treatment with CXCR4 antagonist, impairing Tregs function, could improve the anticancer immune response, in combination with conventional therapy and/or immunotherapy such as checkpoints inhibitors.

KW - CXCR4

KW - Immune suppression

KW - Renal cell carcinoma

KW - T regulatory cells

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85030315454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030315454&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20363

DO - 10.18632/oncotarget.20363

M3 - Article

AN - SCOPUS:85030315454

VL - 8

SP - 77110

EP - 77120

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -